CSS LLC’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

CSS LLC’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,000	Closed	-$180K	–	1003
2020 Q3	$180K	Buy	+10,000	New	+$207K	0.01%	585

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CSS LLC's DRNA Position: Q4 2020 in Review

CSS LLC sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2020, closing a stake of 10,200 shares — an estimated $183K sold.

CSS LLC first reported a position in DRNA in Q3 2020 and held it in 1 quarter. The position peaked at $183K in Q3 2020. 173 funds tracked by Wall St. Rank hold DRNA as of Q4 2020.

CSS LLC reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
CSS LLC sold 10,200 Dicerna Pharmaceuticals, Inc. shares in Q4 2020, an estimated $183K.
CSS LLC first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2020 and held it in 1 quarter.
CSS LLC's Dicerna Pharmaceuticals, Inc. position peaked at $183K in Q3 2020.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2020.

Based on CSS LLC's 13F filing for Q4 2020, filed 16 Feb 2021.